Challenging business environment for the API for “Livalo” due to the impact of generic drugs
First written in FY2017-Q1. 13 of 27 entries say "Restated". Latest entry: FY2026-H1.
Nissan Chemical moved to the "Worse" side of this theme in 2019.
0 other companies' latest entry also says "Reframed".
- FY2026-H1ReframedAnnual report
「Revenue from Livaro active pharmaceutical ingredients for overseas markets increased.」
Regarding Livaro active pharmaceutical ingredients, for which revenue had declined both in Japan and overseas during the previous interim period, the explanation this time states that overseas revenue increased. - FY2025-H1RestatedAnnual report
「Revenue from Livaro active pharmaceutical ingredients declined both in Japan and overseas.」
As in the first and second quarters of the previous fiscal year, the explanation states that revenue from Livaro active pharmaceutical ingredients declined both in Japan and overseas. - FY2024-Q2RestatedAnnual report
「Revenue from Livaro active pharmaceutical ingredients declined both in Japan and overseas.」
As in the previous quarter, the explanation states that revenue from Livaro active pharmaceutical ingredients declined both in Japan and overseas. - FY2024-Q1WorsenedAnnual report
「Revenue from Livaro active pharmaceutical ingredients declined both in Japan and overseas.」
While full-year revenue in the previous fiscal year was described as being in line with the previous year, revenue declined both in Japan and overseas in the first quarter under review. - FY2023ReframedAnnual report
「Revenue from Livaro active pharmaceutical ingredients was in line with the previous year.」
The explanation has shifted from declining overseas shipments through the most recent quarter to revenue being in line with the previous year for the full year. The challenging environment itself, due to the expiration of the domestic patent and generic drugs, remains an ongoing risk. - FY2023-Q3RestatedAnnual report
「Overseas shipments of Livaro active pharmaceutical ingredients declined.」
As in the previous quarter, the explanation states that overseas shipments of Livaro active pharmaceutical ingredients declined, with no substantive change confirmed in the challenging business environment, including the impact of generic drugs. - FY2023-Q2RestatedAnnual report
「Overseas shipments of Livaro active pharmaceutical ingredients remained firm.」
As in the previous quarter, the explanation states that overseas shipments of Livaro active pharmaceutical ingredients remained firm. - FY2023-Q1ReframedAnnual report
「Overseas shipments of Livaro active pharmaceutical ingredients remained firm.」
The explanation has shifted from lower revenue due to the growing presence of generic drugs overseas through the previous quarter to firm overseas shipments this time. - FY2022-Q3ReframedAnnual report
「Livaro active pharmaceutical ingredients, a treatment for hypercholesterolemia, generated higher revenue in Japan, but lower revenue overseas due to the impact of the growing presence of generic drugs.」
The explanation has shifted from focusing on lower revenue both in Japan and overseas, or lower overseas revenue, to a regional situation in which revenue increased in Japan but declined overseas due to the growing presence of generic drugs. - FY2022-Q2ReframedAnnual report
「Livaro active pharmaceutical ingredients, a treatment for hypercholesterolemia, generated higher revenue in Japan, but lower revenue overseas due to the impact of the growing presence of generic drugs.」
While lower revenue due to the growing presence of generic drugs continued overseas, revenue increased in Japan, changing the regional picture from the previous quarter, when revenue declined both in Japan and overseas. - FY2022-Q1ReframedAnnual report
「Livaro active pharmaceutical ingredients, a treatment for hypercholesterolemia, generated lower revenue due to the growing presence of generic drugs overseas.」
Although lower revenue due to the growing presence of generic drugs continues as before, this time the cause of the decline is explicitly identified as the growing presence of generic drugs overseas. - FY2021-Q3RestatedAnnual report
「Livaro active pharmaceutical ingredients, a treatment for hypercholesterolemia, generated lower revenue due to the impact of the growing presence of generic drugs.」
The explanation states that lower revenue from Livaro active pharmaceutical ingredients due to the growing presence of generic drugs continues. - FY2021-Q2RestatedAnnual report
「Livaro active pharmaceutical ingredients, a treatment for hypercholesterolemia, generated lower revenue due to the impact of the growing presence of generic drugs.」
The explanation states that lower revenue from Livaro active pharmaceutical ingredients due to the growing presence of generic drugs continues. - FY2021-Q1RestatedAnnual report
「Livaro active pharmaceutical ingredients, a treatment for hypercholesterolemia, generated lower revenue due to the impact of the growing presence of generic drugs both in Japan and overseas.」
The explanation states that lower revenue due to the growing presence of generic drugs continues both in Japan and overseas, with no substantive change in the existing business environment. - FY2020-Q3WorsenedAnnual report
「The selling price of Livaro active pharmaceutical ingredients, a treatment for hypercholesterolemia, declined both in Japan and overseas due to the growing presence of generic drugs, resulting in lower revenue.」
The decline in selling prices due to the growing presence of generic drugs affected both Japan and overseas and has continued to result in lower revenue. - FY2020-Q2WorsenedAnnual report
「The selling price of Livaro active pharmaceutical ingredients, a treatment for hypercholesterolemia, declined both in Japan and overseas due to the growing presence of generic drugs, resulting in lower revenue.」
The decline in selling prices due to the growing presence of generic drugs affected both Japan and overseas, resulting not only in lower sales but also in lower revenue. - FY2020-Q1WorsenedAnnual report
「Although the selling price of Livaro active pharmaceutical ingredients, a treatment for hypercholesterolemia, declined both in Japan and overseas due to the growing presence of generic drugs, shipments remained firm.」
Previously, the explanation focused primarily on declining domestic sales, but this time it states that the decline in selling prices due to the growing presence of generic drugs affected both Japan and overseas. Shipments, however, remained firm. - FY2019-Q3RestatedAnnual report
「Livaro active pharmaceutical ingredients performed well overseas, including in South Korea and other markets, but declined in Japan due to the growing presence of generic drugs.」
The situation of strong overseas sales alongside declining domestic sales due to the growing presence of generic drugs continues to be described. The decline in domestic sales due to generic drugs is stated as an actual sales result. - FY2019-Q2ReframedAnnual report
「Shipments of Livaro active pharmaceutical ingredients, a treatment for hypercholesterolemia, increased due to shipments for overseas markets being brought forward.」
While both domestic and overseas sales had declined in the previous quarter, the explanation states that they increased this quarter due to overseas shipments being brought forward, shifting the explanation for the decline to include shipment timing. It does not state that the impact of generic drugs has been resolved. - FY2019-Q1WorsenedAnnual report
「Livaro active pharmaceutical ingredients declined both in Japan and overseas, but FineTech, a pharmaceutical research and development participation business, performed steadily.」
Previously, overseas sales had increased while domestic sales declined due to the growing presence of generic drugs, but this time the explanation states that the decline in Livaro active pharmaceutical ingredients sales affected both Japan and overseas. - FY2018RestatedAnnual report
「Overseas shipments of Livaro active pharmaceutical ingredients increased, while domestic shipments decreased due to the growing presence of generic drugs.」
The situation of declining domestic sales due to the growing presence of generic drugs alongside increasing overseas sales continued to be described for the full year. - FY2018-Q3RestatedAnnual report
「Livaro active pharmaceutical ingredients increased overseas but decreased in Japan due to the growing presence of generic drugs.」
The continued situation is described as declining domestic sales due to the growing presence of generic drugs alongside increasing overseas sales. - FY2018-Q2RestatedAnnual report
「Livaro active pharmaceutical ingredients increased overseas but decreased in Japan due to the growing presence of generic drugs.」
The continued situation is described as declining domestic sales due to the growing presence of generic drugs alongside increasing overseas sales. - FY2018-Q1RestatedAnnual report
「Livaro active pharmaceutical ingredients increased overseas but decreased in Japan due to the growing presence of generic drugs.」
The continued situation is described as declining domestic sales due to the growing presence of generic drugs alongside increasing overseas sales. - FY2017RestatedAnnual report
「Livaro active pharmaceutical ingredients increased overseas but decreased in Japan due to the growing presence of generic drugs.」
The same situation continued to be described for the full year: domestic sales declined due to the growing presence of generic drugs, while overseas sales increased. - FY2017-Q3WorsenedAnnual report
「Shipments of Livaro active pharmaceutical ingredients decreased in Japan due to the growing presence of generic drugs, but increased overseas, particularly to Asia.」
The decline in domestic sales due to the growing presence of generic drugs is explicitly stated, showing the risk's impact as an actual decline. Overseas sales, particularly to Asia, increased. - FY2017-Q1First statedAnnual report
「Although the Livaro active pharmaceutical ingredients business continues to face challenging conditions due to the impact of generic drugs, sales volume exceeded the previous year both in Japan and overseas during the quarter under review.」
While the impact of generic drugs is described as an ongoing risk, sales volume during the quarter under review was reported to have exceeded the previous year.